JP2020531524A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020531524A5 JP2020531524A5 JP2020511314A JP2020511314A JP2020531524A5 JP 2020531524 A5 JP2020531524 A5 JP 2020531524A5 JP 2020511314 A JP2020511314 A JP 2020511314A JP 2020511314 A JP2020511314 A JP 2020511314A JP 2020531524 A5 JP2020531524 A5 JP 2020531524A5
- Authority
- JP
- Japan
- Prior art keywords
- her2
- mva
- cancer
- cells
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17187824.2 | 2017-08-24 | ||
| EP17187824 | 2017-08-24 | ||
| PCT/EP2018/072789 WO2019038388A1 (en) | 2017-08-24 | 2018-08-23 | POLYTHERAPY FOR THE TREATMENT OF CANCER BY INTRAVENOUS ADMINISTRATION OF RECOMBINANT MVA AND ANTIBODY |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020531524A JP2020531524A (ja) | 2020-11-05 |
| JP2020531524A5 true JP2020531524A5 (OSRAM) | 2022-09-07 |
| JP7202362B2 JP7202362B2 (ja) | 2023-01-11 |
Family
ID=59702586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511314A Active JP7202362B2 (ja) | 2017-08-24 | 2018-08-23 | 組み換えｍｖａ及び抗体の静脈内投与を用いた、がん治療のための併用療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11273211B2 (OSRAM) |
| EP (1) | EP3691675A1 (OSRAM) |
| JP (1) | JP7202362B2 (OSRAM) |
| KR (1) | KR102754876B1 (OSRAM) |
| CN (1) | CN111050790B (OSRAM) |
| AU (1) | AU2018320417B2 (OSRAM) |
| BR (1) | BR112020003669A2 (OSRAM) |
| CA (1) | CA3073310A1 (OSRAM) |
| IL (1) | IL272546B2 (OSRAM) |
| MX (1) | MX2020001856A (OSRAM) |
| SG (1) | SG11202001115TA (OSRAM) |
| WO (1) | WO2019038388A1 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| CN114980920A (zh) | 2019-11-18 | 2022-08-30 | 詹森生物科技公司 | 基于突变体calr和jak2的疫苗及其用途 |
| US20230059344A1 (en) * | 2019-11-20 | 2023-02-23 | Bavarian Nordic A/S | Medical Uses of 4-1BBL Adjuvanted Recombinant Modified Vaccinia Virus Ankara (MVA) |
| CN114867491B (zh) * | 2019-11-20 | 2025-08-15 | 巴法里安诺迪克有限公司 | 用于肿瘤内和/或静脉内施用以治疗癌症的重组mva病毒 |
| US12194157B2 (en) | 2020-04-09 | 2025-01-14 | Finncure Oy | Carrier for targeted delivery to a host |
| AU2021252164A1 (en) | 2020-04-09 | 2022-12-15 | Finncure Oy | Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses |
| EP4171619A4 (en) * | 2020-06-26 | 2024-08-07 | National Breast Cancer Coalition | BREAST CANCER VACCINE |
| WO2022009052A2 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| WO2022192268A1 (en) * | 2021-03-10 | 2022-09-15 | University Of Iowa Research Foundation | Methods of enhancing antibody therapies |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766598A (en) | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products |
| EP2112225A1 (en) | 1996-07-25 | 2009-10-28 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Recombinant pox virus for immunization against tumor-associated antigens |
| EP1865065A1 (en) * | 1998-12-09 | 2007-12-12 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | A recombinant vector expressing multiple costimulatory molecules and uses thereof |
| CN101676389A (zh) | 2000-11-23 | 2010-03-24 | 巴法里安诺迪克有限公司 | 改良安卡拉痘苗病毒变体 |
| EP1461073B1 (en) | 2001-11-30 | 2010-01-06 | The Government of the United States of America, as represented by the Secretary Department of Health and Human Services | Peptide agonists of prostate-specific antigen, and uses therefor |
| AU2002356690B2 (en) | 2001-12-04 | 2008-07-24 | Bavarian Nordic A/S | Flavivirus NS1 subunit vaccine |
| CN100558894C (zh) * | 2003-07-21 | 2009-11-11 | P.安杰莱蒂分子生物学研究所 | 编码人表皮生长因子2/neu抗原的合成基因及其用途 |
| WO2010060632A1 (en) | 2008-11-27 | 2010-06-03 | Bavarian Nordic A/S | Promoters for recombinant viral expression |
| US8394385B2 (en) | 2009-03-13 | 2013-03-12 | Bavarian Nordic A/S | Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines |
| EP3320915A1 (en) * | 2009-04-17 | 2018-05-16 | Globeimmune, Inc. | Combination immunotherapy compositions against cancer and methods |
| US10111946B2 (en) | 2012-06-22 | 2018-10-30 | Bavarian Nordic A/S | Poxviral vectors for low antibody response after a first priming immunization |
| US10973892B2 (en) | 2012-09-04 | 2021-04-13 | Bavarian Nordic A/S | Methods and compositions for enhancing vaccine immune responses |
| ES2752190T3 (es) * | 2012-09-14 | 2020-04-03 | Us Health | Proteína Brachyury, vectores adenovirales que codifican proteína Brachyury y su uso |
| WO2014043535A1 (en) * | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions for the treatment of cancer |
| US20150283220A1 (en) | 2012-10-19 | 2015-10-08 | Bavarian Nordic, Inc. | Methods and compositions for the treatment of cancer |
| WO2014063832A1 (en) | 2012-10-28 | 2014-05-01 | Bavarian Nordig A/S | Pr13.5 promoter for robust t-cell and antibody responses |
| US9725494B2 (en) * | 2013-05-17 | 2017-08-08 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Soluble CD27 (sCD27) and the use thereof |
| CA2928199C (en) * | 2013-11-05 | 2025-06-17 | Bavarian Nordic A/S | POLYTHERAPY FOR CANCER TREATMENT USING A POXVIRUS EXPRESSING A TUMOR ANTIGEN AND AN ANTAGONIST AND/OR AGONIST OF AN IMMUNE CHECKPOINT INHIBITOR |
| MX377258B (es) * | 2013-11-28 | 2025-03-07 | Bavarian Nordic As | Composiciones de vectores poxvirus y su uso para inducir una respuesta inmunitaria. |
| AU2015259510B2 (en) * | 2014-05-13 | 2020-10-01 | Bavarian Nordic A/S | Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist |
| WO2016007499A1 (en) | 2014-07-07 | 2016-01-14 | Duke University | Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same |
| WO2016046357A1 (en) * | 2014-09-26 | 2016-03-31 | Bavarian Nordic A/S | Methods and compositions for intra-nasal immunization with recombinant mva encoding flagellin |
| US11753652B2 (en) | 2015-07-31 | 2023-09-12 | Bavarian Nordic A/S | Cassette encoding a FPV/brachyury fusion protein |
| CN113056284A (zh) * | 2018-11-20 | 2021-06-29 | 巴法里安诺迪克有限公司 | 通过肿瘤内和/或静脉内施用编码4-1bbl(cd137l)和/或cd40l的重组mva治疗癌症的疗法 |
| US20230059344A1 (en) * | 2019-11-20 | 2023-02-23 | Bavarian Nordic A/S | Medical Uses of 4-1BBL Adjuvanted Recombinant Modified Vaccinia Virus Ankara (MVA) |
| EP4452305A1 (en) * | 2021-12-23 | 2024-10-30 | Bavarian Nordic A/S | Recombinant mva viruses for intraperitoneal administration for treating cancer |
-
2018
- 2018-08-23 JP JP2020511314A patent/JP7202362B2/ja active Active
- 2018-08-23 CA CA3073310A patent/CA3073310A1/en active Pending
- 2018-08-23 IL IL272546A patent/IL272546B2/en unknown
- 2018-08-23 SG SG11202001115TA patent/SG11202001115TA/en unknown
- 2018-08-23 KR KR1020207005076A patent/KR102754876B1/ko active Active
- 2018-08-23 MX MX2020001856A patent/MX2020001856A/es unknown
- 2018-08-23 US US16/641,236 patent/US11273211B2/en active Active
- 2018-08-23 BR BR112020003669-2A patent/BR112020003669A2/pt unknown
- 2018-08-23 EP EP18756447.1A patent/EP3691675A1/en active Pending
- 2018-08-23 CN CN201880054776.8A patent/CN111050790B/zh active Active
- 2018-08-23 AU AU2018320417A patent/AU2018320417B2/en active Active
- 2018-08-23 WO PCT/EP2018/072789 patent/WO2019038388A1/en not_active Ceased
-
2022
- 2022-03-14 US US17/693,716 patent/US11723964B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11723964B2 (en) | Combination therapy for treating cancer with an antibody and intravenous administration of a recombinant MVA | |
| AU2019385665B2 (en) | Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-ibbl (cd137l) and/or cd40l | |
| JP7644111B2 (ja) | がんを治療するための腫瘍内及び／または静脈内投与用組み換えｍｖａウイルス | |
| JP7555334B2 (ja) | 組み換えｍｖａ、及び免疫チェックポイントアンタゴニストまたは免疫チェックポイントアゴニストの静脈内投与によって、がんを治療する併用療法 | |
| WO2023118508A1 (en) | Recombinant mva viruses for intraperitoneal administration for treating cancer | |
| US20250002606A1 (en) | Combination Therapy for Treating Cancer with an Antibody and Intravenous Administration of a Recombinant MVA | |
| RU2795103C2 (ru) | Комбинированная терапия для лечения рака путем внутривенного введения рекомбинантного mva и антитела | |
| CA3240596A1 (en) | Therapy for modulating immune response with recombinant mva encoding il-12 |